



Fresenius Kabi – Recall of ketorolac injection

- On December 17, 2020, [Fresenius Kabi announced](#) a voluntary, user level recall of one lot of [ketorolac](#) injection, due to particulate matter.
- The recalled lot is listed below.

Product Description	NDC#	Lot# (Expiration Date)
Ketorolac injection 60 mg/2 mL, 2 mL fill in a 2 mL amber vial	63323-162-02	6121125 (02/2021)

- Ketorolac tromethamine is indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
- Administration of ketorolac injection containing particulate matter could obstruct blood vessels and result in local irritation of blood vessels, swelling at the site of injection, a mass of tissue that could become inflamed and infected, blood clots travelling to the lung, scarring of the lung tissues, and allergic reactions that could lead to life-threatening consequences.
- To date, no adverse events have been reported to Fresenius Kabi related to this recall.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled ketorolac injection.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Fresenius Kabi Medical Affairs at **1-800-551-7176** for further information about the recall or the Fresenius Kabi Quality Assurance Department at **1-866-716-2459** for information on how to return product.
-



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.